Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98)
Authors:
- Reinhard ZenhäusernRZReinhard Zenhäusern
- on behalf of the Swiss Group for Clinical Cancer Research (SAKK)O(on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
Open Access
- 1 September 2008
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 93 (9) , 1426-1428
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997Journal of Clinical Oncology, 2007
- Herpes simplex and Epstein-Barr virus lymphadenitis in a patient with chronic lymphocytic leukemia treated with fludarabineEuropean Journal of Haematology, 2006
- Richter’s Transformation in Chronic Lymphocytic LeukemiaSeminars in Oncology, 2006
- Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemiaBlood, 2003
- Advances in the treatment of hairy-cell leukaemiaThe Lancet Oncology, 2003
- Epstein–Barr Virus-Positive B-Cell Lymphoproliferative Disorders Arising in Immunodeficient Patients Previously Treated With Fludarabine for Low-Grade B-Cell NeoplasmsAmerican Journal of Surgical Pathology, 2002
- Rituximab, a chimaeric anti‐CD20 monoclonal antibody, in the treatment of hairy cell leukaemiaBritish Journal of Haematology, 2001
- The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disordersBritish Journal of Haematology, 1999
- HAIRY‐CELL LEUKAEMIA: BIOLOGY AND MANAGEMENTBritish Journal of Haematology, 1999
- Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.Journal of Clinical Oncology, 1997